Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression

Progress in Cardiovascular Diseases

Volumn 52, Issue 2, 2009, Pages 153-167

  Artham, Surya M ^a   Lavie, Carl J ^a   Milani, Richard V ^a   Patel, Dharmendrakumar A ^a   Verma, Anil ^a   Ventura, Hector O ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; LOSARTAN; MINOXIDIL; NIFEDIPINE; PERINDOPRIL; TELMISARTAN;

AEROBIC EXERCISE; ANGINA PECTORIS; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY FLOW RESERVE; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; M MODE ECHOCARDIOGRAPHY; MORTALITY; NONHUMAN; OBESITY; PROGNOSIS; RISK ASSESSMENT; SODIUM RESTRICTION; TREATMENT RESPONSE; VASODILATATION;

ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CORONARY CIRCULATION; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 69249220247     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2009.05.002     Document Type: Article

References (115)

1. Lavie C.J., Ventura H.O., and Messerli F.H. Regression of increased left ventricular mass by antihypertensives. Drugs 42 (1991) 945-961
2. Messerli F.H., Ventura H.O., Elizardi D.J., et al. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 77 (1984) 18-22
3. Lavie C.J., Ventura H.O., and Messerli F.H. Left ventricular hypertrophy. Its relationship to obesity and hypertension. Postgrad Med 91 (1992) 131-143
4. Messerli F.H. Cardiovascular effects of obesity and hypertension. Lancet 1 (1982) 1165-1168
5. Lavie C.J., and Messerli F.H. Cardiovascular adaptation to obesity and hypertension. Chest 90 (1986) 275-279
6. Lavie C.J., Milani R.V., and Messerli F.H. Prevention and reduction of left ventricular hypertrophy in the elderly. Clin Geriatr Med 12 (1996) 57-68
7. Lavie C.J., Ventura H.O., and Messerli F.H. Left ventricular hypertrophy in the elderly. Cardiol Elderly 2 (1994) 362-369
8. Milani R.V., Lavie C.J., Mehra M.R., et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 97 (2006) 959-963
9. Lavie C.J., Milani R.V., Ventura H.O., et al. Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol 98 (2006) 1396-1399
10. Lavie C.J., Milani R.V., Shah S.B., et al. Impact of left ventricular geometry on prognosis-A review of Ochsner studies. Ochsner J 8 (2008) 11-17
11. Katz A.M. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 322 (1990) 100-110
12. Veterans Administration Cooperative Study on Antihypertensive Agents. Double blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents; preliminary results. Arch Intern Med 110 (1962) 230-236
13. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
14. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
15. Aronow W.S., Epstein S., Kuenigsberg M., et al. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia, and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden death among elderly patients. Am J Cardiol 62 (1988) 1124-1125
16. Casale P.N., Devereux R.B., Milner M., et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105 (1986) 173-178
17. Schmieder R.E., Messerli F.H., Sturgill D., et al. Cardiac performance after reduction of myocardial hypertrophy. Am J Med 87 (1989) 22-27
18. Lavie C.J., Milani R.V., Mehra M.R., et al. Hypertension and left ventricular hypertrophy in the elderly. In: Tresch D.D., and Aronow W.S. (Eds). Cardiovascular disease in the elderly patient. 2nd ed. (1998), Marcel Dekker, Inc, New York 109-127
19. Lavie C.J., Ventura H.O., and Messerli F.H. Cardiopathy of obesity. Int Med Spec 9 (1988) 57-71
20. Lee M., Gardin J.M., Lynch J.C., et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study. Am Heart J 133 (1997) 36-43
21. de Simone G., Celentano A., and Devereux R. Metabolic risk factors and left ventricular hypertrophy. Nutr Metab Cardiovac Dis 8 Suppl 5 (1998) 40-45
22. de Simone G., Palmieri V., Bella J.N., et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 20 (2002) 323-331
23. Jilaihawi H., Greaves S., Rouleau J.L., et al. Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. Am J Cardiol 91 (2003) 723-726
24. Kannel W.B., Gordon T., Castelli W.P., et al. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham study. Ann Intern Med 72 (1970) 813-822
25. Carabello B.A. The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. J Heart Valve Dis Suppl 2 (1995) S132-S138
26. Drazner M.H., Dries D.L., Peshock R.M., et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 4 (2005) 124-129
27. Olsen M.H., Wachtell K., Hermann K.L., et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J 144 (2002) 530-537
28. Malatino L.S., Cataliotti A., Benedetto F.A., et al. Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension 41 (2003) 88-92
29. Brush S.E., Cannon R.O., Schenke W.H., et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 319 (1988) 1302-1307
30. Levy D., Anderson K.M., Savage D.D., et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 60 (1987) 560-565
31. Cooper R.S., Simmons B.E., Castaner A., et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 65 (1990) 441-445
32. Schillaci G., Verdecchia P., Porcellati C., et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35 (2000) 580-586
33. Lauer M.S., Anderson K.M., Kannel W.B., et al. The impact of obesity on left ventricular mass and geometry: the Framingham Heart Study. JAMA 266 (1991) 231-236
34. Marcus M.L., Koyanayi S., Harrison D.G., et al. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 75 (1983) 62-66
35. Devereux R.B., Roman M.J., Liu J.E., et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 86 (2000) 1090-1096
36. Mathew J., Lonn E., Johnstone D., et al. Left ventricular hypertrophy by electrocardiogram predicts death and development of heart failure in high-risk patients without systolic dysfunction. J Am Coll Cardiol 35 Suppl A (2000) 212A Abstract
37. Okin P.M., Devereux R.B., Nieminen M.S., et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 113 (2006) 67-73
38. Kannel W.B. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 75 (1983) 4-11
39. Kannel W.B. Hypertension in the elderly: epidemiologic appraisal from the Framingham study. Cardiol Elderly 1 (1993) 359-363
40. Marcus M.L., Harrison D.G., Chilian W.M., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 75 (1987) 119-125
41. Krauser D.G., and Devereux R.B. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 31 (2006) 305-316
42. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
43. Villari B., Campbell S.E., Hess O.M., et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 22 (1993) 1477-1484
44. Wachtell K., Bella J.N., Rokkedal J., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. Circulation 105 (2002) 1071-1076
45. Lavie C.J., Amodeo C., Ventura H.O., et al. Left atrial abnormalities indicating diastolic ventricular dysfunction in cardiopathy of obesity. Chest 92 (1987) 1042-1046
46. Wang M., Gabriel W.K., Wang A., et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. J Hypertens 23 (2005) 183-191
47. Cuocolo A., Sax F.L., Brush J.E., et al. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanisms for systolic dysfunction during exercise. Circulation 81 (1990) 978-986
48. Galzerano D., Tammaro P., del Viscovo L., et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 18 (2005) 1563-1569
49. Granier P., Esquerre J.P., Tredez P., et al. Correlations between M-mode markers of left ventricular hypertrophy and radionuclide angiographic indices of left ventricular diastolic function in mild to moderate hypertension. J Hypertens 7 (1989) S100-S101
50. McLenachan J.M., Henderson E., Morris K.I., et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 317 (1987) 787-792
51. Kannel W.B., and Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 5 (1985) 141B-149B
52. Lavie C.J., Ventura H.O., Messerli F.H., et al. Hypertension, obesity, left ventricular hypertrophy, complex ventricular ectopic activity, and increased risk for sudden death: Review of Ochsner Studies and the literature. J Cardiopulm Rehabil 13 (1993) 264-270
53. Haider A.W., Larson M.G., Benjamin E.J., et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 (1998) 1454-1459
54. Wachtell K., Okin P.M., Olsen M.H., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. Circulation 116 (2007) 700-705
55. Verdecchia P., Reboldi G., Gattobigio R., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 41 (2003) 218-223
56. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
57. Okin P.M., Wachtell K., Devereux R.B., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296 (2006) 1242-1248
58. Levy D., Garrison R.J., Savage D.D., et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. Ann Intern Med 110 (1989) 101-107
59. Drazner M.H., Rame J.E., Marino E.K., et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43 (2004) 2207-2215
60. Koren M.J., Ulin R.J., Koren A.T., et al. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15 (2002) 1021-1028
61. Boner G., Cooper M.E., McCarroll K., et al. Adverse effects of left ventricular hypertrophy in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Diabetologia 48 (2005) 1980-1987
62. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
63. Lavie C.J., Milani R.V., Ventura H.O., et al. Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 100 (2007) 1460-1464
64. Patel D.A., Lavie C.J., Milani R.V., et al. Left atrial volume index and left ventricular geometry independently predict mortality in 16,904 elderly patients with preserved ejection fraction, abstracted. J Am Coll Cardiol 53:10 Suppl A (2009) A273
65. Patel D.A., Lavie C.J., Milani R.V., et al. Impact of left atrial volume index and left ventricular geometry on mortality in obese versus non-obese elderly patients with preserved ejection fraction, abstracted. J Am Coll Cardiol 53:10 Suppl A (2009) A238
66. Patel D., Lavie C.J., Milani R.V., et al. Disparate effects of left ventricular geometry and obesity on mortality in women with preserved systolic function-"the obesity paradox" in women. Circulation 118 (2008) S1153
67. Patel D., Lavie C.J., Milani R.V., et al. Left ventricular geometry predicts mortality in 26,216 women with preserved systolic function. Circulation 118 (2008) S602
68. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 55 (1977) 613-618
69. Levy D., Labib S.B., Anderson K.M., et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 81 (1990) 815-820
70. Levy D., Anderson K.M., Savage D.D., et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med 108 (1988) 7-13
71. Bluemke D.A., Kronmal R.A., Lima J.A., et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 52 (2008) 2148-2155
72. Lavie C.J., Milani R.V., Patel D., et al. Disparate effects of obesity and left ventricular geometry on mortality in 8,088 elderly patients with preserved systolic function. Postgrad Med 121 (2009) In press
73. De Simone S.R., Daniels R.B., Devereux R.A., et al. Left ventricular mass in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20 (1992) 1251-1260
74. Williams B., Lacy P.S., Thom S.M., et al., and CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 113 (2006) 1213-1225
75. Roman M.J., Devereux R.B., Kizer J.R., et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart study. Hypertension 50 (2007) 197-203
76. Nagano M., Higaki J., Mikami H., et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 9 (1991) 595-599
77. Helmcke J.G., Schneckloth R., Corcoran A.C., et al. Electrocardiographic changes of left ventricular hypertrophy: effects of antihypertensive treatment. Am Heart J 53 (1957) 549-557
78. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 7 (1985) 105-112
79. Prineas R.J., Rautaharju P.M., Grandits G., et al. Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the Multiple Risk-Factor Intervention Trial. J Electrocardiol 34 (2001) 91-101
80. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
81. Fouad F.M., Nakashima Y., Tarazi R.C., et al. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control. Am J Cardiol 49 (1982) 795-801
82. Wachtell K., Palmieri V., Olsen M.H., et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 106 (2002) 227-232
83. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 (1998) 48-54
84. Levy D., Salomon M., D'Agostino R.B., et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90 (1994) 1786-1793
85. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2350-2356
86. Devereux R.B., Dahlöf B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
87. Okin P.M., Devereux R.B., Jern S., et al., for the LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292 (2004) 2343-2349
88. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
89. Okin P.M., Devereux R.B., Harris K.E., et al., for the LIFE Study investigators. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) Study. Hypertension 50 (2007) 984-990
90. Okin P.M., Devereux R.B., Harris K.E., et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 147 (2007) 311-319
91. MacMahon S.W., Wilcken D.E.L., and McDonald G.J. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 314 (1986) 334-339
92. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
93. Dahlöf B., Pennert K., and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 5 (1992) 95-110
94. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 275 (1996) 1507-1513
95. Devereux R.B., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 104 (2001) 1248-1254
96. Trimarco B., De Luca N., Ricciardelli B., et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 62 (1988) 745-750
97. Sadoshima J., and Izumo S. Molecular characterization of angiotensin II: induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 73 (1993) 413-423
98. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
99. Beevers G., Lip G.Y.H., and O'Brien E. ABC of Hypertension. 4th ed. (2001), BMJ Books, London
100. Kuperstein R., and Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: a randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 102 (2000) 1802-1806
101. Muiesan M.L., Salvetti M., Rizzoni D., et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13 (1995) 1091-1105
102. Neaton J.D., Grimm Jr. R.H., Prineas R.J., et al., for the treatment of mild hypertension research group. Treatment of Mild Hypertension Study: final results. JAMA 270 (1993) 713-724
103. Devereux R.B., Palmieri V., Liu J.E., et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 20 (2002) 1445-1450
104. Berglund T., Dahlof B., Sever P., et al. Differential regression of electrocardiographic left ventricular hypertrophy by amlodipine versus atenolol in the ASCOT trial. J Hypertens. 26 Suppl 1 (2008) S254
105. Solomon S.D., Appelbaum E., Manning W.J., et al. Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119 (2009) 530-537
106. Leibson P.R. Left ventricular hypertrophy. Curr Treat Options Cardiovasc Med 1 (1999) 219-230
107. Gosse P., Sheridan D.J., Zannad F., et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 18 (2000) 1465-1475
108. Bakris G.L., Tarka E.A., Waterhouse B., et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol 98 (2006) 46-52
109. De Luca N., et al., on behalf of the REASON Project investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 22 (2004) 1623-1630
110. Dahlof B., et al. The PICXEL study: benefit of perindopril/indapamide on LVH reduction. J Hypertens 22 Suppl 2 (2004) S410
111. MacMahon S., Collins G., Rautaharju P., et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the multiple risk factor intervention trial. Am J Cardiol 63 (1989) 202-210
112. Schmeider R.E., Messerli F.H., Garavaglia G.E., et al. Dietary salt intake: a determinant of cardiac involvement in essential hypertension. Circulation 78 (1988) 951-956
113. Leichman J.G., Wilson E.B., Scarborough T., et al. Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med 121 (2008) 966-973
114. Sjöström L., Narbro K., Sjöström C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752
115. Sjöström C.D., Peltonen M., Wedel H., et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36 (2000) 20-25